RDHL vs. MGTA, CARM, KZR, RMTI, THAR, EGRX, EQ, CASI, CLNN, and AADI
Should you be buying RedHill Biopharma stock or one of its competitors? The main competitors of RedHill Biopharma include Magenta Therapeutics (MGTA), Carisma Therapeutics (CARM), Kezar Life Sciences (KZR), Rockwell Medical (RMTI), Tharimmune (THAR), Eagle Pharmaceuticals (EGRX), Equillium (EQ), CASI Pharmaceuticals (CASI), Clene (CLNN), and Aadi Bioscience (AADI). These companies are all part of the "medical" sector.
Magenta Therapeutics (NASDAQ:MGTA) and RedHill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation.
RedHill Biopharma has higher revenue and earnings than Magenta Therapeutics.
Magenta Therapeutics has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500. Comparatively, RedHill Biopharma has a beta of 3.47, indicating that its share price is 247% more volatile than the S&P 500.
47.5% of Magenta Therapeutics shares are held by institutional investors. Comparatively, 7.2% of RedHill Biopharma shares are held by institutional investors. 15.2% of Magenta Therapeutics shares are held by insiders. Comparatively, 6.8% of RedHill Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, RedHill Biopharma had 4 more articles in the media than Magenta Therapeutics. MarketBeat recorded 4 mentions for RedHill Biopharma and 0 mentions for Magenta Therapeutics. Magenta Therapeutics' average media sentiment score of 1.23 beat RedHill Biopharma's score of 0.95 indicating that RedHill Biopharma is being referred to more favorably in the news media.
Magenta Therapeutics' return on equity of 0.00% beat RedHill Biopharma's return on equity.
RedHill Biopharma received 270 more outperform votes than Magenta Therapeutics when rated by MarketBeat users. Likewise, 68.76% of users gave RedHill Biopharma an outperform vote while only 57.09% of users gave Magenta Therapeutics an outperform vote.
Summary
RedHill Biopharma beats Magenta Therapeutics on 9 of the 11 factors compared between the two stocks.
Get RedHill Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RedHill Biopharma Competitors List
Related Companies and Tools
